Chk1反义寡核苷酸影响胶质瘤放疗敏感性的研究(3)
 |
| 第1页 |
参见附件。
[3] Crooke S T.Progression in antisense technology：the end of the beginning[J].Methods Enzymol，2000：313(3)：33-45.
[4] Shapiro G，Kaelin J W.Anticancer drug targets：cell cycle and checkpoint control[J].J Clin Invest，1999：104(4)：1645.
[5] Sugimoto K，Sasaki M，Isobe Y，et al.Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1[J].Oncogene，2008，27(22)：3091-3101.
[6] Yan Y，Black C，Cowan K.Irradiation-induced G2/M checkpoint response requires ERK1/2 activation[J].Oncogene，2007，26(32)：4689-4698.
[7] Bourke E，Brown J，Takeda S，et al.DNA damage induces Chk1-dependent threonine-160 phosphorylation and activation of Cdk2[J].Oncogene，2010，29(4)：616-624.
[8] Choi S，Lyu S，Park W.Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of akt[J].Archives of Pharmacal Research，2004，27(1)：68-76.
[9] Wraight C J，White P J.Antisense oligonucleotides in cutaneous therapy[J].Pharmacolopy & Therapeutics，2001，90(1)，89-104.
[10] Hirose Y， Berger M S，Pieper R O，et al.Abrogation of the Chk1-mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human gliblastoma cells[J].Caner Res，2001，61(15)：5843-5849.
(收稿日期：2012-03-01) (本文编辑：连胜利)
您现在查看是摘要介绍页，详见PDF附件(3805kb)。